Prof. Dan Peer is a Full Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU).

From Oct. 2020 he is the Vice President for Research & Development at Tel Aviv University. From 2016-2020, he was the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals and from 2017 he is the Founding and Managing Director of SPARK Tel Aviv, Center for Translational Medicine at TAU.

Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) as drug discovery tools in immune cells. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA to cells to induce therapeutic gene expression of desired proteins. This has enormous applications in cancer, inflammation and infection diseases. In addition, he pioneered the use of targeted lipid nanoparticles as carriers for molecular medicines (gene silencing, gene expression and gene editing).

Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration. In addition, based on his work, five spin-off companies were generated aiming to bring innovative personalized molecular medicines into clinical practice using precision nanotechnology.

Prof. Peer is a scientific advisory board member in more than 15 companies and on the scientific advisory board of 20 journals. He is a past President of the Israeli Chapter of the Controlled Release Society, and a Past Member of the Board of the Israel Young Academy.